Introduction: Among uterine tumors resembling ovarian sex cord tumors (UTROSCTs), it has been suggested that
GREB1-rearranged cases are biologically distinct from
ESR1-rearranged cases and might be considered as a separate entity.
Objectives: The aim of this systematic review was to assess the difference between
GREB1- and
ESR1-rearranged UTROSCTs with regard to several clinico-pathological parameters.
Methods: Three electronic databases were searched from their inception to February 2025 for all studies assessing the presence of
GREB1 and
ESR1 rearrangements in UTROSCTs. Exclusion criteria comprised overlapping patient data, case reports, and reviews. Statistical analysis was performed to compare clinicopathological variables between
GREB1- and
ESR1-rearranged UTROSCTs. Dichotomous variables were compared by using Fisher’s exact test; continuous variables were compared by using Student’s
t-test. A
p-value < 0.05 was considered significant.
Results: Six studies with 88 molecularly classified UTROSCTs were included. A total of 36 cases were
GREB1-rearranged, and 52 cases were
ESR1-rearranged.
GREB1-rearranged UTROSCTs showed a significantly older age (
p < 0.001), larger tumor size (
p = 0.002), less common submucosal/polypoid growth (
p = 0.005), higher mitotic index (
p = 0.010), more common LVSI (
p = 0.049), and higher likelihood to undergo hysterectomy (
p = 0.008) compared to
ESR1-rearranged cases. No significant differences were detected with regard to margins, cytological atypia, necrosis, retiform pattern, and rhabdoid cells. No significant differences were found in the immunohistochemical expression of any of the assessed markers (wide-spectrum cytokeratins, α-inhibin, calretinin, WT1, CD10, CD56, CD99, smooth muscle actin, desmin, h-caldesmon, Melan-A/MART1, SF1, or Ki67).
GREB1-rearranged UTROSCTs showed significantly lower disease-free survival compared to
ESR1-rearranged UTROSTCs (
p = 0.049).
Conclusions: In conclusion,
GREB1-rearranged UTROSCTs occur at an older age, are less likely to display a submucosal/polypoid growth, and exhibit larger size, a higher mitotic index, more common lymphovascular space invasion, and lower disease-free survival compared to
ESR1-rearranged UTROSCTs. Nonetheless, the similar immunophenotype suggests that they belong to the same tumor family. Further studies are necessary to confirm this point.
Full article